药物涂层球囊治疗冠状动脉药物洗脱支架内再狭窄临床分析

目的分析药物涂层球囊(DCB)在治疗冠状动脉药物涂层支架内再狭窄病变中的疗效。方法回顾性分析20例冠状动脉药物洗脱支架内再狭窄患者接受药物涂层球囊治疗的临床资料及随访结果。结果 20例患者共21处再狭窄病变接受DCB治疗,术中即刻成功率95.23%,1处病变在应用DCB治疗后并发夹层并出现TIMI 2级血流,然后植入药物洗脱支架(DES)治疗。所有病例术后随访至今无心绞痛再发,未发生主要心血管不良事件。其中12例患者在术后6~9个月接受冠状动脉造影复查,复查时靶病变最小管腔直径与术后即刻直径比较,按病变血管统计,差异无统计学意义(P0.05);合计统计比较差异有统计学意义(P0.05)。结论 DCB治疗DES支架内再狭窄即刻及短期疗效肯定,可以作为支架内再狭窄的一种新的治疗手段。     

药物洗脱球囊治疗支架内再狭窄的研究进展

正经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)经历了30年的发展历程,而减少术后再狭窄一直是人们努力的方向。单纯经皮冠状动脉腔内成形术(percutaneous transluminal coronary angioplasty,PTCA)再狭窄高达39%~67%[1],裸金属支架(bare-metal stent,BMS)置入术后再狭窄可达5%~35%[2],药物洗脱支架(drug-eluting stent,DES)置入术后再狭窄仍达5%~10%[3]。近些年来出现了预防介入治疗术后血管再狭窄的新技术—药物洗脱球囊     

药物涂层球囊在治疗冠状动脉药物涂层支架内再狭窄病变中的疗效

目的 研究药物涂层球囊在治疗冠状动脉药物涂层支架内再狭窄病变中的疗效。方法 运用随机数字表法,将2020年1月至2023年1月该院收治的冠状动脉药物涂层支架再狭窄患者（n=60）分为对照组（n=30,实施药物洗脱支架治疗）和研究组（n=30,实施药物涂层球囊治疗）。比较各组干预疗效、不良事件发生情况。结果 研究组干预总有效率97.38%高于对照组75.95%(P<0.05)。两组不良事件发生率对比无差异（P>0.05）。结论 药物涂层球囊可显著提高冠状动脉药物涂层支架再狭窄的总体干预效果,且不会增加不良事件发生风险。     

冠状动脉药物洗脱支架内再狭窄的最新研究进展

药物洗脱支架（DES）的诞生和不断优化已经大大提高了经皮冠状动脉介入治疗（PCI）的安全性和有效性,但随着病例复杂性的增加和DES的超适应证应用,术后再狭窄率正逐年上升。因此,当前DES时代下,支架内再狭窄（ISR）仍是临床上亟待解决的一大难题。本文将主要就DES置入后ISR发生发展的病理机制、组织病理学及治疗策略的最新研究成果及进展进行综述。     

复发性支架内再狭窄的研究进展

复发性支架内再狭窄(R-ISR)是指初次支架内再狭窄(ISR)病变经过成功介入治疗后再次发生同一部位的支架内狭窄。目前,ISR是国内外研究的重点,而对于反复ISR的研究较少,但随着越来越多的患者接受经皮冠状动脉介入治疗支架植入术治疗,且ISR发生率无降低趋势,治疗过的ISR患者存在再次发生ISR的风险,所以R-ISR是一个不容忽视的问题。R-ISR的发生发展与ISR的发生发展因素相似,但却不尽相同。最近的研究探索了各种R-ISR的预测因素和治疗策略。现对R-ISR的发生率、发生机制、危险因素、腔内影像学评估、治疗选择和现有知识的空白等方面进行讨论。     

药物涂层球囊对老年患者下肢动脉粥样硬化闭塞症支架内再狭窄的疗效

目的探究老年下肢动脉粥样硬化闭塞症中股浅动脉支架内再狭窄行药物球囊治疗后效果。方法 28例(28条肢体)股浅动脉支架后再狭窄患者中狭窄19例,闭塞9例。根据临床治疗方式分为普通球囊血管成形术14例(A组)和药物涂层球囊血管成形术14例(B组)。结果28例均手术成功,手术时间60~100 min,术中均未出现相关并发症。术后数字化减影血管造影术(DSA)显示靶血管形态及通畅性均良好。术后给予常规用药,住院1 w,出院后常规双抗用药;均获得随访3~12个月。术后6个月通畅率A组78.60%(11/14)、B组100.00%(14/14);12个月通畅率A组64.30%(9/14)、B组85.70%(12/14);两组差异显著(P<0.05)。术后无截肢或死亡病例。结论对于股浅动脉支架内再狭窄患者行药物涂层球囊治疗较普通球囊血管成形术的近中期通畅率有显著提高。     

药物涂层球囊在下肢动脉硬化闭塞症支架内再狭窄治疗中的应用观察

目的 观察药物涂层球囊(DCB)在下肢动脉硬化闭塞症支架植入术后支架内再狭窄(ISR)治疗中的应用效果.方法 选取ISR患者30例(30条肢体),均接受DCB治疗.观察术后12个月靶血管初级通畅情况,治疗6、12月时Rutherford分级改善情况及治疗12月时临床驱动的靶病变血运重建(CD-TLR)和踝肱指数(ABI...     

冠状动脉支架内再狭窄治疗的一缕曙光——药物涂层球囊问世

<正>自1977年瑞士Gruentzig医师首次在苏黎世使用经皮冠状动脉球囊扩张成形术(PTCA)治疗冠心病以来,人类相继研发了众多的经皮冠状动脉介入技术用以攻克冠心病。这些治疗技术的最大好处是能够立刻开通狭窄或闭塞的血管,恢复已减少或中断的冠状动脉血流,使冠心病得以控制,减低病死率,提高生活质量。并且以其创伤小、恢复快而为患     

紫杉醇涂层球囊导管与紫杉醇涂层支架在治疗支架内再狭窄方面的对比

背景：用紫杉醇涂层球囊导管治疗支架内再狭窄与普通球囊血管成形术比较,6个月时的晚期腔径丢失率非常低,而且2年以内的主要不良心脏事件发生亦较少。我们将紫杉醇涂层球囊的疗效和安全性在现行标准下与紫杉醇洗脱支架进行了对比。     

准分子激光冠状动脉成形术联合药物涂层球囊在复发性支架内再狭窄病变中的运用探讨

目的 探讨准分子激光冠状动脉成形术联合药物涂层球囊的治疗策略在复发性支架内再狭窄病变中运用的安全性和疗效。方法 回顾性连续纳入2019年10月至2023年4月在中国人民解放军总医院第一医学中心采用准分子激光冠状动脉成形术联合药物涂层球囊进行治疗的27例复发性支架内再狭窄患者（30处病变）的临床资料进行分析。收集患者基线资料、冠状动脉造影及介入数据、住院期间并发症发生数据,并在术后1、3、6个月进行随访,记录重大临床事件发生情况。结果 27例患者,平均年龄（66.4±9.8）岁,共计30处（100%）病变均取得了手术成功和治疗成功,患者住院期间无急性心肌梗死、无冠状动脉穿孔及心脏压塞、无紧急的靶病变再次血运重建、无死亡。6个月的随访,无急性心肌梗死、无死亡发生,共2例患者（共2处病变）接受了靶病变再次血运重建（1例患者进行了重复的药物球囊扩张术,1例接受了冠状动脉旁路移植术）。结论 准分子激光冠状动脉成形术联合药物涂层球囊是治疗复发性支架内再狭窄安全、有效的治疗策略,但尚需更多的研究进一步验证。     

Long-term angiographic follow-up after successful repeat balloon angioplasty for in-stent restenosis

BACKGROUND: Coronary stent implantation is associated with improved angiographic short-term and mid-term clinical outcome. However, restenosis rate still remains between 20 and 30%. HYPOTHESIS: The purpose of the study, performed as a prospective angiographic follow-up to detect restenosis, was to evaluate the immediate and the 6-month angiographic results of repeat balloon angioplasty for in-stent restenosis. METHODS: From April 1996 to September 1997, 335 stenting procedures performed in 327 patients underwent prospectively 6-month control angiography. Of the 96 lesions that showed in-stent restenosis (> 50% diameter stenosis) (29%), 72 underwent balloon angioplasty. RESULTS: The primary success rate was 100%. Follow-up angiogram at a mean of 6.9 +/- 2.4 months was obtained in 54 patients. Recurrent restenosis was observed in 24 of the 55 stents (44%). Repeat intervention for diffuse and body location in-stent restenosis before repeat intervention was associated with significantly higher rates of recurrent restenosis (p < 0.001 and p < 0.05, respectively). Of the 19 patients who underwent further balloon angioplasty (100% success rate), coronary angiography was performed in 18 (95%) at a mean of 8.2 +/- 2.0 months and showed recurrent restenosis in 12 patients (67%). Further repeat intervention for diffuse and severe in-stent restenosis before the second repeat intervention was associated with significantly higher rates of further recurrent restenosis (p < 0.05 and p < 0.005, respectively). CONCLUSIONS: Although balloon angioplasty can be safely, successfully, and repeatedly performed after stent restenosis, it carries a progressively high recurrence of angiographic restenosis rate during repeat 6-month follow-ups. The subgroup of patients with diffuse, severe, and/or body location in-stent restenosis proved to be at higher risk of recurrent restenosis.     

Cutting balloon angioplasty to treat carotid in-stent restenosis

We describe a case of carotid artery restenosis following carotid artery stenting for treatment of post-endarterectomy stenosis. The goal is to highlight the risk of recurrent restenosis following endarterectomy. In this case report, we describe the use of cutting balloon therapy as a reasonable alternative to repeat surgical revascularization.     

Intravascular ultrasound-guided balloon angioplasty for treatment of in-stent restenosis.

We investigated the usefulness of intravascular ultrasound (IVUS)-guided balloon angioplasty for in-stent restenosis in 37 lesions of 34 consecutive patients. We divided these patients into two groups: a group in which the balloon size was determined by quantitative coronary angiography (QCA group; 17 patients, 19 lesions) and a group in which the balloon size was determined by IVUS (IVUS group; 17 patients, 18 lesions). We compared short-term and 6-month outcomes for these groups. In the IVUS group, we used a balloon of a size equal to 95% of the media-to-media diameter at the distal to the stent, as determined by IVUS. No significant differences were observed in patient or lesion characteristics between the two groups. The clinical success rate was 100% in both groups, and no clinical events were observed in either of the groups. The balloon/artery ratio was larger in the IVUS group than in the QCA group (1.33 +/- 0.35 vs. 1.16 +/- 0.13, P < 0.05), and the recurrent restenosis rate was lower (17% vs. 53%, P < 0.05). These results suggest that repeat balloon angioplasty using a balloon size determined by IVUS is useful for in-stent restenosis. Cathet. Cardiovasc. Intervent. 47:298-303, 1999.     

Cutting balloon angioplasty for the treatment of in-stent restenosis.

The results using the Cutting Balloon for the treatment of in-stent restenosis may be superior to those of conventional percutaneous transluminal coronary angioplasty (PTCA) or even the combination of PTCA preceded by rotational atherectomy. The reasons for these possible differences are not yet well defined. The case we report suggests that the Cutting Balloon achieves a better final result than conventional PTCA, by making the tissue more amenable to being pushed outward through the stent struts.     

联合应用切割球囊与放射治疗对冠脉支架内再狭窄的作用

目的 :探讨联合应用切割球囊及β射线 （1 66Ho）冠脉内放射治疗对支架内再狭窄的作用。方法 :对 2 0 0 1- 0 1～2 0 0 2 - 0 3韩国亚洲大学医院心脏中心完成的 6 0例支架内再狭窄的患者 ,全部使用切割球囊预扩张 ,满意扩张后使用充满液态 1 66Ho的长球囊 （30～ 40 mm ）进行冠脉内放射治疗。术后随访主要临床不良事件 ,并于术后 8个月行冠状动脉造影 ,用 MEDCON Viewer软件包进行定量冠状动脉造影 （QCA）分析。结果 :6 0例患者 6 5处支架内再狭窄病变均被满意扩张 ,血管内放射治疗全部成功 ,无撕裂、血栓形成等并发症。随访 8个月 ,无 1例死亡。 5例 （8.3%）于术后 3个月出现心绞痛行靶病变血管重建术 ,其余 5 5例患者均于术后 8个月行冠状动脉造影 ,4例于支架内发生再狭窄 （7.3%） ,6例于支架边缘发生再狭窄 （10 .9%） ,全部患者无晚期血栓形成、假性动脉瘤及冠状动脉瘤发生。病变长度为 2 5 .1± 4.7mm。晚期管腔丧失为 0 .19± 0 .6 8mm。最小管腔直径术前为 0 .38± 0 .2 6 mm ,术后即刻为 2 .0 8± 0 .36 m m ,8个月随访时为 1.82± 0 .76 mm。结论 :联合应用切割球囊及β射线 （1 66Ho）冠脉内放射治疗对支架内再狭窄是有效及安全的 ,可在临床推广应用。     

Coronary artery pseudoaneurysm after balloon angioplasty and intracoronary beta-radiation for in-stent restenosis.

Intracoronary brachytherapy is an effective method for treating in-stent restenosis. We report a case of coronary artery pseudoaneurysm after balloon angioplasty and intracoronary beta-radiation. The pseudoaneurysm was treated successfully with implantation of two coronary stent grafts.